From January 1975 to December 1979, 14 consecutive patients with advanced (stage III-IV) diffuse lymphocytic, poorly differentiated lymphoma (DLPD) were treated with adriamycin, bleomycin, vinblastine and DTIC (ABVD). Either maintenance combination chemotherapy with CVP or radiotherapy over bulky disease was added in the cases with complete response (CR). Fifty per cent of the patients achieved CR and 80% achieved objective responses. Among CRs, 100% were alive at 2 years, 70% of them without evidence of disease. Overall, 75% of the patients were alive at 2 years, 30% without evidence of disease. Toxicity was acceptable and no drug-related deaths occurred. ABVD is not the ideal combination for DLPD, but it should be taken into consideration in patients with advanced DLPD in which first line combination chemotherapy regimens are not successful.
Get full access to this article
View all access options for this article.
References
1.
ArmitageP.: Statistical Methods in Medical Research. p. 399, Blackwell Scientific Publications, Oxford, 1971.
2.
BonadonnaG.MonfardiniS.VillaE.: Non-cross-resistant combinations in stage IV non-Hodgkin's lymphomas.Cancer Treat. Rep., 61: 11117–1123, 1977.
3.
BonadonnaG.SantoroA.ZucaliR.ValagussaP.: Improved 5-year survival in advanced Hodgkin's disease by combined modality approach.Cancer Clin. Trials, 2: 217–226, 1979.
4.
CarboneP.P.KaplanH.S.MusshofK.SmithersD.W.TubianaM.: Report of the Committe on Hodgkin's disease Staging Classification.Cancer Res., 31: 1860–1861, 1971.
5.
Discussion III: Chemotherapy of the non-Hodgkin's lymphomas.Cancer Treat. Rep., 61: 1126, 1977.
6.
EzdinliE.Z.CostelloW.LenhardR.E.Jr., BakemeierR.BennettJ.M.BerardC.W.CarboneP.P.: Survival of nodular versus diffuse pattern lymphocytic poorly differentiated lymphoma.Cancer, 41: 1990–1996, 1978.
7.
EzdinliE.PocockS.BerardC.W.AungstC.W.SilversteinM.HortonJ.BennettJ.BakemeierR.StolbachL.Jr., PerliaC.BrunkS.F.LenhardR.E.KlaassenD.J.RicterP.CarboneP.: Comparison of intensive versus moderate chemotherapy of lymphocytic lymphomas.Cancer, 38: 1060–1068, 1976.
8.
FreiE.III, SchlossmanS.IsraelM.: New approaches to treatment of non-Hodgkin's lymphoma.Cancer Treat. Rep., 61: 1209–1217, 1977.
9.
GarrettT.J.GeeT.S.DowlingM.D.LeeB.J.MiddlemanM.P.ClarksonB.D.YoungC.W.: Cyclophosphamide L2 protocol: A combination chemotherapeutic regimen for advanced non-Hodgkin's lymphoma.Cancer Treat. Rep., 61: 7–16, 1977.
10.
GarvinA.J.SimonR.YoungR.C.De VitaV.T.BerardC.W.: The Rappaport classifications of non Hodgkin's lymphomas: A close look using other proposed classifications.Semin. Oncol., 7: 234–243, 1980.
11.
GriswoldD.P.LasterW.R.ShabelF.M.: Therapeutic potentiation by adriamycin and 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide against B 16 melanoma, C3H breast carcinoma, Lewis lung carcinoma and leukemia L 1210.Proc. Am. Assoc. Cancer Res., 14: 15, 1973.
12.
HarrisonD.T.NeimanP.E.SullicanK.KafermanM.RudolphR.H.EinsteinA.B.Jr..: Combined modality therapy for advanced, diffuse, lymphocytic and histiocytic lymphomas.Cancer, 42: 1697–1704, 1978.
13.
KennedyB.J.BloomfieldC.D.KiangD.T.VosikaG.PetersonB.A.TheologidesA.: Combination versus successive single agent chemotherapy in lymphocytic lymphoma.Cancer, 41: 23–28, 1978.
